PMID- 22672302 OWN - NLM STAT- MEDLINE DCOM- 20121019 LR - 20231011 IS - 1755-5949 (Electronic) IS - 1755-5930 (Print) IS - 1755-5930 (Linking) VI - 18 IP - 6 DP - 2012 Jun TI - NPY intraperitoneal injections produce antidepressant-like effects and downregulate BDNF in the rat hypothalamus. PG - 487-92 LID - 10.1111/j.1755-5949.2012.00314.x [doi] AB - AIMS: Several studies have documented an involvement of Neuropeptide Y (NPY) in stress-related disorders. Stress-related disorders are also characterized by changes in brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), neurotrophins implicated in the survival and function of neurons. Thus the aim of this study was to investigate whether an NPY intraperitoneal treatment has antidepressant-like effects in rats subjected to a classical stress paradigm, the Forced Swim Test (FST), in association with changes in local brain neurotrophin production. METHODS: Rats were intraperitoneally injected with either NPY (60 mug/kg) or a vehicle for three consecutive days between two FST sessions and then tested for time spent (or delay onset) in immobile posture. Moreover, we measured by enzyme-linked immunosorbent assay (ELISA) neurotrophin levels in the hypothalamus and corticosterone levels in plasma. RESULTS: The data showed that NPY induced a significant delay in the onset and a significant reduction in the duration of the immobility posture in FST. We also found that NPY decreased BDNF levels in the hypothalamus and corticosterone levels in plasma. DISCUSSION: Immobility posture in FST can be reduced by antidepressant drugs. Thus, our data show an antidepressant-like effect of NPY associated with changes in BDNF levels in the hypothalamus and reduced activity of hypothalamic-pituitary-adrenal (HPA) axis. CONCLUSION: These findings, while confirming the involvement of the NPY system in stress-related disorders, suggest that a less invasive route of administration, such as an intraperitoneal injection, may be instrumental in coping with stressful events in animal models and perhaps in humans. CI - (c) 2012 Blackwell Publishing Ltd. FAU - Gelfo, Francesca AU - Gelfo F AD - Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy. FAU - Tirassa, Paola AU - Tirassa P FAU - De Bartolo, Paola AU - De Bartolo P FAU - Croce, Nicoletta AU - Croce N FAU - Bernardini, Sergio AU - Bernardini S FAU - Caltagirone, Carlo AU - Caltagirone C FAU - Petrosini, Laura AU - Petrosini L FAU - Angelucci, Francesco AU - Angelucci F LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - CNS Neurosci Ther JT - CNS neuroscience & therapeutics JID - 101473265 RN - 0 (Antidepressive Agents) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Neuropeptide Y) RN - 9061-61-4 (Nerve Growth Factor) RN - W980KJ009P (Corticosterone) SB - IM MH - Analysis of Variance MH - Animals MH - Antidepressive Agents/*administration & dosage MH - Body Weight/drug effects MH - Brain-Derived Neurotrophic Factor/*metabolism MH - Corticosterone/blood MH - *Depression/drug therapy/metabolism/pathology MH - Disease Models, Animal MH - Down-Regulation/*drug effects MH - Eating/drug effects MH - Enzyme-Linked Immunosorbent Assay MH - Hypothalamus/*metabolism MH - Male MH - Nerve Growth Factor/metabolism MH - Neuropeptide Y/*administration & dosage MH - Rats MH - Rats, Wistar MH - Swimming/psychology MH - Time Factors PMC - PMC6493532 COIS- The authors declare no conflict of interest. EDAT- 2012/06/08 06:00 MHDA- 2012/10/20 06:00 PMCR- 2012/06/04 CRDT- 2012/06/08 06:00 PHST- 2012/06/08 06:00 [entrez] PHST- 2012/06/08 06:00 [pubmed] PHST- 2012/10/20 06:00 [medline] PHST- 2012/06/04 00:00 [pmc-release] AID - CNS314 [pii] AID - 10.1111/j.1755-5949.2012.00314.x [doi] PST - ppublish SO - CNS Neurosci Ther. 2012 Jun;18(6):487-92. doi: 10.1111/j.1755-5949.2012.00314.x.